Literature DB >> 15364057

Molecular interactions regulate BCR signal inhibition by CD22 and CD72.

Lars Nitschke1, Takeshi Tsubata.   

Abstract

The inhibitory coreceptors CD22 and CD72 downmodulate B-cell receptor (BCR) signaling and function as a molecular switch, determining whether antigen-stimulated B cells undergo apoptosis or proliferation. These coreceptors carry an intrinsic property for associating with the BCR, and this association is crucial for the initiation of signal inhibition through phosphorylation of these coreceptors by BCR-associated kinases. Recent findings have demonstrated that signal inhibition by these coreceptors is regulated by ligands for the coreceptors and by molecules binding to the coreceptors or the BCR. Moreover, signal inhibition by CD22 depends on the BCR isotype. These findings suggest a dynamic regulation of these coreceptors through molecular interactions on the B-cell surface.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364057     DOI: 10.1016/j.it.2004.08.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  21 in total

Review 1.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

Review 2.  Role of B cell inhibitory receptor polymorphisms in systemic lupus erythematosus: a negative times a negative makes a positive.

Authors:  Naoyuki Tsuchiya; Zen-Ichiro Honda; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2006-09-01       Impact factor: 3.172

3.  Dendritic cell-dependent inhibition of B cell proliferation requires CD22.

Authors:  Lorna Santos; Kevin E Draves; Mark Boton; Prabhjit K Grewal; Jamey D Marth; Edward A Clark
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

4.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

5.  In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.

Authors:  T N C Ramya; Eranthie Weerapana; Lujian Liao; Ying Zeng; Hiroaki Tateno; Liang Liao; John R Yates; Benjamin F Cravatt; James C Paulson
Journal:  Mol Cell Proteomics       Date:  2010-02-19       Impact factor: 5.911

6.  Intravital quantification reveals dynamic calcium concentration changes across B cell differentiation stages.

Authors:  Raluca A Niesner; Anja E Hauser; Carolin Ulbricht; Ruth Leben; Asylkhan Rakhymzhan; Frank Kirchhoff; Lars Nitschke; Helena Radbruch
Journal:  Elife       Date:  2021-03-22       Impact factor: 8.140

7.  The pan-B cell marker CD22 is expressed on gastrointestinal eosinophils and negatively regulates tissue eosinophilia.

Authors:  Ting Wen; Melissa K Mingler; Carine Blanchard; Benjamin Wahl; Oliver Pabst; Marc E Rothenberg
Journal:  J Immunol       Date:  2011-12-21       Impact factor: 5.422

8.  The blood-borne sialyltransferase ST6Gal-1 is a negative systemic regulator of granulopoiesis.

Authors:  Christopher W L Dougher; Alexander Buffone; Michael J Nemeth; Mehrab Nasirikenari; Eric E Irons; Paul N Bogner; Joseph T Y Lau
Journal:  J Leukoc Biol       Date:  2017-05-26       Impact factor: 4.962

9.  Peripheral CD27-CD21- B-cells represent an exhausted lymphocyte population in hepatitis C cirrhosis.

Authors:  Hiroyoshi Doi; Shiroh Tanoue; David E Kaplan
Journal:  Clin Immunol       Date:  2013-12-17       Impact factor: 3.969

10.  B cell-targeted therapies in autoimmunity: rationale and progress.

Authors:  Paolo Fiorina; Mohamed H Sayegh
Journal:  F1000 Biol Rep       Date:  2009-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.